Today: 27 January 2026
Subscribe
Browse Category

Healthcare Industry News 8 November 2025 - 21 November 2025

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO) is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion.…
21 November 2025
····
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after…
20 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday, November 20, 2025, Novo Nordisk’s U.S.-listed ADR (ticker NVO) is trading around $49, roughly in line with Wednesday’s close, after…
20 November 2025
····
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug…
17 November 2025
···
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UNH Stock Forecast for 2026: Can UnitedHealth Survive the DOJ Storm and Medicare Cuts? (Updated November 15, 2025)

UnitedHealth Group’s UNH stock has become one of the most controversial names in the Dow in 2025. After a brutal sell-off driven by a massive cyberattack, rising medical costs and intensifying federal investigations, the stock is trying to stage a comeback — but faces a regulatory and political overhang unlike anything in its history. This analysis pulls together the latest…
15 November 2025
···
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from…
14 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals pushing cheaper copycat products. The move follows the company’s bankruptcy exit and dovetails with a broader U.S. pricing framework announced…
12 November 2025
··
Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg…
11 November 2025
···
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck…
10 November 2025
··
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks…
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key…
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. What happened today Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued…
8 November 2025
····
1 … 6 7 8 9 10

Stock Market Today

  • Believe S.A. (BLV.PA) Pre-Market at €17.20 Eyes Oversold Bounce on EURONEXT
    January 26, 2026, 11:41 PM EST. Believe S.A. (BLV.PA) trades at €17.20 in EURONEXT pre-market, with volume near average at 19,984 shares. The stock shows a negative EPS of -0.03 and a price-to-earnings (P/E) ratio of -573.33, reflecting recent losses despite revenue growth. Technicals reveal the price above 50- and 200-day moving averages, supporting a short-term rebound setup. Confirming a bounce requires a volume surge above average and a break past €17.80 resistance. Meyka AI assigns a B-grade hold rating and forecasts 21.2% upside to €20.85 within 12 months. Mixed analyst views persist, including a strong sell recommendation from third-party ratings. Investors should monitor liquidity and fundamental risks amid volatile earnings in this Consumer Cyclical player.
Go toTop